Citizens Jmp Raises Progyny (NASDAQ:PGNY) Price Target to $33.00

Progyny (NASDAQ:PGNY) had its price objective upped by stock analysts at Citizens Jmp from $31.00 to $33.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price target would suggest a potential upside of 25.12% from the company’s current price.

Several other research firms also recently issued reports on PGNY. Weiss Ratings downgraded shares of Progyny from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Wall Street Zen downgraded shares of Progyny from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 8th. Leerink Partners set a $38.00 price objective on shares of Progyny in a report on Wednesday, July 22nd. Finally, Jefferies Financial Group set a $33.00 target price on shares of Progyny in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.36.

Progyny Stock Performance

Shares of NASDAQ:PGNY opened at $26.38 on Tuesday. The business’s 50 day simple moving average is $28.91 and its two-hundred day simple moving average is $23.85. The firm has a market cap of $2.02 billion, a P/E ratio of 28.56, a PEG ratio of 1.79 and a beta of 0.99. Progyny has a 52-week low of $16.10 and a 52-week high of $33.06.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. The firm had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, equities analysts forecast that Progyny will post 1.25 earnings per share for the current fiscal year.

Progyny declared that its Board of Directors has authorized a share repurchase program on Tuesday, May 26th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 10.3% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Institutional Trading of Progyny

A number of institutional investors and hedge funds have recently modified their holdings of PGNY. Caitong International Asset Management Co. Ltd bought a new stake in Progyny during the fourth quarter worth $25,000. Public Employees Retirement System of Ohio bought a new position in Progyny in the 2nd quarter valued at $29,000. Nykredit A S purchased a new stake in shares of Progyny during the 2nd quarter valued at $38,000. Hantz Financial Services Inc. increased its position in shares of Progyny by 79.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after purchasing an additional 742 shares during the last quarter. Finally, Toth Financial Advisory Corp bought a new stake in shares of Progyny during the 2nd quarter worth $65,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.